Please login to the form below

Not currently logged in
Email:
Password:

Patient adherence co gains £10m investment

Atlantis Healthcare, the patient adherence organisation, has received a £10m investment from White Cloud Capital enabling further expansion

Atlantis Healthcare, a UK-based company that develops and manages health psychology, marketing and communications programmes to ensure patients adhere to their treatment regimes, has received a £10m investment from international investment company White Cloud Capital. The investment will allow Atlantis, which operates in nine countries, to expand further into Europe, Asia and the Middle East, as well as to extend its service offering and R&D capabilities.

The expansion comes at a time of growth in the incidence of chronic conditions, such as diabetes, which coincides with the increasing importance of patient adherence. 

"Our initiatives match the increasing emphasis being placed on actual patient outcomes as a basis for healthcare funding, as opposed to the traditional model of funding according to patient numbers," said Kate Reid, Atlantis UK general manager. "Across Europe and the UK, governments are looking to ensure the treatments they fund can be guaranteed to improve population health in a cost-effective way. That means developing innovative ways of working — especially in the primary care pathways — and that's exactly what we are doing."

With 45 patient programmes operational worldwide, Atlantis Healthcare is already established internationally, with customers including Pfizer, Novartis and the New Zealand Ministry of Health. Its Australian division has been the recipient of two PRIME Customer Focus awards and an Australian Direct Marketing Association (ADMA) Effectiveness Award.

20th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics